Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

This condition has been described by Michael J. Stephen in his 2021 book “Breath Taking” as the “most frustrating and disheartening of all the diseases in pulmonary medicine.” Over a frighteningly ...

Discover how weather conditions affect idiopathic pulmonary fibrosis (IPF) symptoms and learn practical tips to manage your ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical trial data.

Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This groundbreaking medication goes beyond merely alleviating ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...